Sort by
Keyphrases
Moderate to Severe
100%
Alzheimer's Disease
100%
Donepezil
100%
Memantine
100%
Multicenter RCT
100%
Domino
100%
Severe Alzheimer's Disease
100%
Placebo
40%
Acetylcholinesterase Inhibitors (AChEI)
40%
Mini-Mental State Examination
30%
Cost-effectiveness
20%
Severe Dementia
20%
Wales
10%
Clinical Efficacy
10%
Telephone Interview
10%
Common Cause
10%
Treatment Strategy
10%
Treatment Options
10%
Glutamate Receptor Antagonists
10%
EQ-5D
10%
Health-related Quality of Life
10%
Drug Class
10%
Activities of Daily Living
10%
General Health Questionnaire-12
10%
Neuropsychiatric Inventory Questionnaire (NPI-Q)
10%
Randomized Placebo-controlled Trial
10%
Primary Outcome Measure
10%
Current Control
10%
Best Medical Treatment
10%
Bristol Activities of Daily Living Scale
10%
Non-cognitive
10%
National Institutes of Health
10%
Clinical Excellence
10%
Effective Compounds
10%
Cognitive Dementia
10%
Caregiver Burden
10%
Causes of Dementia
10%
Living at Home
10%
Service Receipt
10%
Client Services
10%
Dementia Symptoms
10%
Anti-dementia Drugs
10%
State Activity
10%
DEMQOL-Proxy
10%
Clinical Transition
10%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Donepezil
100%
Alzheimer's Disease
100%
Memantine
100%
Placebo
45%
Cholinesterase Inhibitor
36%
Glutamate Receptor Antagonist
9%
Nootropic Agent
9%
Neuroscience
Alzheimer's Disease
100%
Donepezil
100%
Memantine
100%
Placebo
45%
Acetylcholinesterase Inhibitor
36%
Glutamic Acid
9%
Neuropsychiatric Symptom
9%